Romero Roberto, Erez Offer, Hüttemann Maik, Maymon Eli, Panaitescu Bogdan, Conde-Agudelo Agustin, Pacora Percy, Yoon Bo Hyun, Grossman Lawrence I
Perinatology Research Branch, Program for Perinatal Research and Obstetrics, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services (NICHD/NIH/DHHS), Bethesda, MD, and Detroit, MI; Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI; Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI; Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI.
Perinatology Research Branch, Program for Perinatal Research and Obstetrics, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services (NICHD/NIH/DHHS), Bethesda, MD, and Detroit, MI; Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI; Department of Obstetrics and Gynecology, Soroka University Medical Center School of Medicine, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel.
Am J Obstet Gynecol. 2017 Sep;217(3):282-302. doi: 10.1016/j.ajog.2017.06.003. Epub 2017 Jun 12.
Metformin is everywhere. Originally introduced in clinical practice as an antidiabetic agent, its role as a therapeutic agent is expanding to include treatment of prediabetes mellitus, gestational diabetes mellitus, and polycystic ovarian disease; more recently, experimental studies and observations in randomized clinical trials suggest that metformin could have a place in the treatment or prevention of preeclampsia. This article provides a brief overview of the history of metformin in the treatment of diabetes mellitus and reviews the results of metaanalyses of metformin in gestational diabetes mellitus as well as the treatment of obese, non-diabetic, pregnant women to prevent macrosomia. We highlight the results of a randomized clinical trial in which metformin administration in early pregnancy did not reduce the frequency of large-for-gestational-age infants (the primary endpoint) but did decrease the frequency of preeclampsia (a secondary endpoint). The mechanisms by which metformin may prevent preeclampsia include a reduction in the production of antiangiogenic factors (soluble vascular endothelial growth factor receptor-1 and soluble endoglin) and the improvement of endothelial dysfunction, probably through an effect on the mitochondria. Another potential mechanism whereby metformin may play a role in the prevention of preeclampsia is its ability to modify cellular homeostasis and energy disposition, mediated by rapamycin, a mechanistic target. Metformin has a molecular weight of 129 Daltons and therefore readily crosses the placenta. There is considerable evidence to suggest that this agent is safe during pregnancy. New literature on the role of metformin as a chemotherapeutic adjuvant in the prevention of cancer and in prolonging life and protecting against aging is reviewed briefly. Herein, we discuss the mechanisms of action and potential benefits of metformin.
二甲双胍随处可见。它最初作为一种抗糖尿病药物引入临床实践,其治疗作用正在不断扩展,包括治疗糖尿病前期、妊娠期糖尿病和多囊卵巢疾病;最近,实验研究和随机临床试验观察表明,二甲双胍在子痫前期的治疗或预防中可能占有一席之地。本文简要概述了二甲双胍治疗糖尿病的历史,并综述了二甲双胍治疗妊娠期糖尿病以及治疗肥胖的非糖尿病孕妇以预防巨大儿的荟萃分析结果。我们着重介绍了一项随机临床试验的结果,该试验中孕早期使用二甲双胍虽未降低大于胎龄儿的发生率(主要终点),但确实降低了子痫前期的发生率(次要终点)。二甲双胍预防子痫前期的机制包括减少抗血管生成因子(可溶性血管内皮生长因子受体-1和可溶性内皮层蛋白)的产生以及改善内皮功能障碍,这可能是通过对线粒体的作用实现的。二甲双胍在预防子痫前期中可能发挥作用的另一个潜在机制是其能够调节细胞内稳态和能量分配,这是由机械靶点雷帕霉素介导的。二甲双胍的分子量为129道尔顿,因此很容易穿过胎盘。有大量证据表明该药物在孕期是安全的。本文还简要综述了关于二甲双胍作为化疗辅助药物在预防癌症、延长寿命和预防衰老方面作用的新文献。在此,我们讨论了二甲双胍的作用机制和潜在益处。